CoChat

Drugs for sleep disorders: mechanisms and therapeutic prospects

Open access
Szabadi, Elemer · 2006 · British Journal of Clinical Pharmacology
Cited by 89

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The past decade has witnessed an explosion of knowledge about the neural mechanisms that control sleep and arousal, triggered by two discoveries relating to the sleep disorder narcolepsy. Narcolepsy is caused by the loss of orexin‐containing neurons in the hypothalamus, and a novel nonstimulant wakefulness‐promoting drug, modafinil, alleviates excessive day‐time sleepiness associated with the disorder. The level of arousal is controlled by an intricate interplay between distinct wakefulness‐ and sleep‐promoting nuclei situated in the hypothalamus and brainstem and the interconnections between the nuclei and the neurotransmitters involved have been mapped. Wakefulness‐promoting nuclei include the orexinergic lateral hypothalamic/perifornical area, the histaminergic tuberomammillary nucleus, the cholinergic pedunculopontine tegmental nucleus, the noradrenergic locus coeruleus, the 5‐hydroxytryptaminergic raphe nuclei and possibly the dopaminergic ventral tegmental area. The major sleep‐promoting nucleus is the GABAergic ventrolateral preoptic nucleus of the hypothalamus. Currently available and future drugs exert their therapeutic effects in the three major classes of sleep disorder (insomnia, hypersomnia, parasomnia) by modifying neurotransmission at distinct sites within the arousal‐controlling neuronal network. This enables classification of therapeutic drugs for sleep disorders on the basis of their modes of action: drugs that interact with the GABAergic sleep‐promoting system, drugs that interact with different wakefulness‐promoting systems and drugs that modulate the level of arousal by mechanisms that do not initially involve the basic network (e.g. melatonin, adenosine). The development of novel therapeutic drugs for sleep disorders is based on the synthesis of molecular/cellular mechanisms and the sites of action within the arousal‐controlling neuronal network.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2006.02680.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Szabadi, E.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2006-05-11
Volume
61
Issue
6
Pages
761-766
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2073460305
Cited by
89
References
8
FWCI
4.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drugs for sleep disorders: mechanisms and therapeutic prospects. https://app.cochat.ai/papers/10.1111/j.1365-2125.2006.02680.x
The paper
Szabadi, E. (2006). Drugs for sleep disorders: mechanisms and therapeutic prospects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2006.02680.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.